Neurofascin (NFASC) gene mutation causes autosomal recessive ataxia with demyelinating neuropathy

Edoardo Monfrini, Letizia Straniero, Sara Bonato, Giacomo Monzio Compagnoni, Andreina Bordoni, Robertino Dilena, Paola Rinchetti, Rosamaria Silipigni, Dario Ronchi, Stefania Corti, Giacomo P. Comi, Nereo Bresolin, Stefano Duga, Alessio Di Fonzo

ARTICLE INFO

Keywords: Neurofascin NFASC Hereditary Ataxia Neuropathy Nodopathy

ABSTRACT

Introduction: Neurofascin, encoded by NFASC, is a transmembrane protein that plays an essential role in nervous system development and node of Ranvier function. Anti-Neurofascin autoantibodies cause a specific type of chronic inflammatory demyelinating polyneuropathy (CIDP) often characterized by cerebellar ataxia and tremor. Recently, homozygous NFASC mutations were recently associated with a neurodevelopmental disorder in two families.

Methods: A combined approach of linkage analysis and whole-exome sequencing was performed to find the genetic cause of early-onset cerebellar ataxia and demyelinating neuropathy in two siblings from a consanguineous Italian family. Functional studies were conducted on neurons from induced pluripotent stem cells (iPSCs) generated from the patients.

Results: Genetic analysis revealed a homozygous p.V1122E mutation in NFASC. This mutation, affecting a highly conserved hydrophilic transmembrane domain residue, led to significant loss of Neurofascin protein in the iPSC-derived neurons of affected siblings.

Conclusions: The identification of NFASC mutations paves the way for genetic research in the developing field of nodopathies, an emerging pathological entity involving the nodes of Ranvier, which are associated for the first time with a hereditary ataxia syndrome with neuropathy.

1. Introduction

Neurofascin, a member of the L1 immunoglobulin cell adhesion molecule family (L1CAM) family, is a transmembrane protein, encoded by NFASC, an evolutionarily conserved gene located on chromosome 1q32, and ubiquitously expressed in human tissues [1]. Neurofascin protein is abundant in the adult central nervous system, especially in the cerebellum and peripheral nerves [2,3]. Moreover, Neurofascin plays a pivotal role in the development and function of the axon initial segment (AIS) and the nodes of Ranvier [4,5]. Both the AIS and node of Ranvier contain a high density of sodium voltage-gated channels, ne-cessary for action potential generation and propagation, which are clustered by interactions with several cytoskeletal and scaffolding proteins, including Neurofascin. Another recognized role of Neurofascin is to connecting the extracellular matrix and glial cells (Schwann cells and oligodendroglia) with the intracellular skeleton of neurons [6–8].

NFASC transcripts undergo extensive alternative splicing and pro-protein isoforms are differentially expressed in the central and peripheral nervous systems in a developmental- and cell type-specific manner. In the adult mouse, Neurofascin has two principal isoforms: the neuronal isoform (138 kDa), known as NF186, and the glial isoform (133 kDa), known as NF155. These proteins are highly glycosylated with observed molecular weights on Western blot of 186 kDa and 155 kDa respectively [9,10]. Similarly, adult human nervous tissues have two principal Neurofascin isoforms with molecular weights of 186 kDa and 150 kDa.

Here, we describe two affected siblings from a consanguineous
Italian family presenting with infantile-onset ataxia and mild demyelinating polyneuropathy who carry a homozygous NFASC missense mutation.

2. Materials and methods

2.1. Clinical data

Patients were subjected to general and neurological examination by an ataxia-experienced neurologist. Both affected individuals underwent brain MRI and neurophysiological studies. Blood samples were collected. The Ethics Committee of the IRCCS Foundation Ca’ Granda Ospedale Maggiore Policlinico (Milan, Italy) approved the study. Written informed consent was obtained from all involved subjects.

2.2. Genetic analysis

Genomic DNA was extracted from peripheral venous blood from all family members by standard salting-out procedures. All subjects were genotyped using the Infinium OmniExpressExome–8 v1.3 BeadChip array, which includes a total of 958,497 markers, with a mean spacing of 3.03 kb. A multipoint parametric linkage analysis was performed using Allegro software (Used map: Illumina 650 k HumanHap v3 deCODE; Inheritance: Recessive; Penetrance: 99%; Scoring function: HOMOZ and MNAllele).

Individual II.1 (see Fig. 1) was analyzed by whole exome sequencing (WES) starting from 50 ng of genomic DNA using the Nextera Rapid Capture Exome Library kit (Illumina, San Diego, CA, USA) and the Ilumina NextSeq500 platform (Illumina) according to the manufacturer instructions. Reads were aligned against the human reference genome (hg19) using BWA [11]. Variant calling was performed with GATK [12] and variant annotation with ANNOVAR (http://annovar.openbioinformatics.org/en/latest/). The candidate variants and their segregation in the family were validated by Sanger sequencing. Primers used for PCR amplification and Sanger sequencing of NFASC and NSMCE4A are listed in Supplementary Table 1.

Array comparative genomic hybridization (array-CGH) was per-formed using an Agilent SurePrint G3 human 4 × 180 K kit. Data were analyzed using CytoGenomics 3.0 (Agilent Technologies, Santa Clara, CA, USA). Aberrations were considered when the involved genomic region was covered by at least three adjacent probes and all arrays showed a derivative log ratio (DLR) spread < 0.2. Genomic co-ordinates were based on the 37 build (February 2009) of the Human Genome Reference Consortium (GRCh37/hg19).

2.3. Cell cultures

Skin punch biopsies were obtained from the ventral part of the left forearm of both affected siblings. Fibroblasts were cultured in DMEM high glucose supplemented with 15% fetal bovine serum (Euroclone, Milan, Italy), 1% penicillin/streptomycin (Sigma-Aldrich, Saint Louis, MO, USA), and 1% of amphotericin B (Sigma-Aldrich).

Fibroblasts were reprogrammed to induced pluripotent stem cells (iPSCs) using the CytoTune-iPS 2.0 Sendai Reprogramming Kit (Life Technologies, Carlsbad, CA, USA). Clones with an iPSC-like morphology underwent karyotype analysis, and those carrying a normal karyotype were used for differentiation (Supplementary Fig. 1A). iPSCs were differentiated to fully mature neurons using the method described by Zhang et al. [13] (Supplementary Table 2 and Supplementary Figs. 1B–C).

2.4. Immunocytofluorescence

Immunocytofluorescence studies were performed according to standard protocols. The iPSCs and neurons were stained with primary antibodies detecting Sox 2 (ab15830, Abcam, Cambridge, UK), Neurofascin (ab31457, Abcam), β-tubulin III (T8660, Sigma-Aldrich), and other markers.
and MAP2 (M90942, Sigma-Aldrich). Alexa Fluor 488 and Alexa Fluor 594 were used as secondary antibodies (Life Technologies). Images were acquired using a Leica SP5 confocal microscope system (Leica Biosystems, Wetzlar, Germany). ImageJ software was used to assess fluorescence intensity [14].

2.5. Protein blotting and sub-cellular fractionation

Whole-protein lysates were obtained by standard methods. Subcellular fractionation was performed using the Subcellular Protein Fractionation Kit for Cultured Cells (Thermo Fisher Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. Fraction-speciﬁc markers were evaluated by Western blot (α-tubulin for cytoplasm; COX-IV for cell and mitochondrial membranes). Western blot analyses were performed in triplicate according to standard procedures using the following primary antibodies: Neurofascin (ab31457, Abcam); α-tubulin (MCA3560Z, AbD Serotec, Kidlington, UK), COX-IV (A21348, Life Technologies), actin (A2066, Sigma-Aldrich). The anti-Neurofascin an-tibody is directed against the intracellular domain of the protein and detects different protein isoforms in human brain (e.g. NF186 and NF155) (Fig. 4A).

2.6. Data availability

The data that support the ﬁndings of this study are available from the corresponding author, upon reasonable request.

3. Results

3.1. Clinical features

The family originated from an isolated valley of Northern Italy. The parents (subjects I.1 and I.2) were ﬁrst cousins (Fig. 1A). The two af- fected siblings were 22 (subject II.1) and 15 (subject II.2) years old at ﬁrst examination. The probands presented an early psychomotor delay and the younger brother exhibited a mild intellectual disability. They started to walk at 3 years of age with an unsteady wide-based ataxic gait. Cerebellar dystar- thria, intention tremor, dysmetria, pursuit sacca-dization, and dyst diadochokinesia were also observed. Eye closing did not worsen ataxic features, suggesting a primary cerebellar involve-ment.

From the age of 11 years, subject II.1 developed progressive spastic hypertonia of the limbs with hyperreflexia, lower limbs intra-rotation, ankle clonus, and bilateral Babinski sign. A therapeutic challenge with baclofen (per os and intrathecal) was not successful. At 16 years of age, she started to use a wheelchair outside the house and required bilateral support for standing. In addition, remarkable sleepiness in the morning appeared, which responded to modafinil (50 mg die). Mild dys-phagia was demonstrated at 18 years of age. At 24 years old, she de-veloped involuntary sub-continuous non-rhythmic myoclonic jerks in the proximal upper limbs, which disappeared during sleep and were aggravated by anxiety and emotions.

Subject II.2 did not develop hypertonia of the limbs or hyperreflexia. From the age of 12 years, he had episodes of aggression and intense anxiety, associated with reality detachment and perseverations. Partial remission of these episodes was achieved with low doses of ar-ipiprazole and paroxetine.

Brain MRI showed mild atrophy of the cerebellum in the older sibling and a mild diffuse T2 hyperintensity of periventricular white matter in both probands, probably due to brain hyponymelination (Fig. 1C). Electroencephalography (EEG) showed bilateral fronto-tem-poral slowing in both probands. The involuntary movements of subject II.1 were not associated with EEG abnormalities. Motor evoked poten-tials (MEPs) showed a marked slowing of the central conduction velo-city in both the upper and lower limbs. Somatosensory evoked poten-tials (SEPs) showed a mild to moderate slowing of the central conduction velocity. Pattern shift visual evoked potentials (VEPs) were within normal limits in II.2, but they could not be reliably assessed in II.1 because of artefacts due to the continuous involuntary movements. However, flash VEPs could be assessed and their latency appeared to be mildly increased. Nerve conduction studies showed a mild length-de-pendent demyelinating sensory-motor peripheral neuropathy, which was more evident in II.2 than in II.1 (Supplementary Table 3). The sensory contribution to axxia was considered to be of minor im-portance considering that the neuropathy was mild and not evident at the neurological examination, the central and peripheral sensory tracts and fibers were less involved than the motor counterparts, and closing the eyes did not worsen the ataxic features.

Muscle biopsies performed on both siblings were unremarkable. Ocular fundus examinations were normal. No cardiovascular abnormalities were found. Standard blood tests were normal.

3.2. Genetic analysis

SCA1, SCA2, SCA3, SCA6, SCA8, SCA10, SCA12, SCA17, DRPLA, and Friedreich’s ataxia pathological expansions were ruled out. Screening for mutations in SCA4, SCA7, SCA8, SCA15, SETX, ARSACS, SCA28, and PLA2G6 was normal. The family pedigree and consanguinity of the parents strongly suggested an autosomal recessive pattern of inheritance, with a homozygous mutation being suspected as the cause of the disease.

Linkage analysis identiﬁed two haploidentical homozygous regions in the two affected individuals on chromosomes 1 and 10 (Fig. 2A). Flanking markers of the homozygous regions were rs4951272-rs11572795 for chromosome 1 and rs2765471-rs716909 for chromo-some 10. A single gene known to be involved in genetic ataxias was present in the linked regions, SYT14 located on chromosome 1 and coding for synaptogamin IV. However, no variants were found in the patients by Sanger sequencing of SYT14 exons and intron-exon boundaries.

WES was performed on subject II.1, obtaining a mean coverage depth of 76.1 with 92% of the bases of the target region having ≥ 20x coverage (97.5% with coverage ≥ 10x). No pathogenic mutations were found in known disease genes for hereditary ataxias, spastic para-plegias, or neuropathies. A ﬁltering analysis for rare (allele fre-quency < 1%) variants with protein impact (missense, nonsense, fra-meshift, inframe ins/del, nonstop, misstart, splice disrup-tive) was performed in the homozygous linkage regions. Only two novel homo-zygous variants were identiﬁed: c.3365 T > A, p.V1122E in NFASC (NM_001005388), and c.754–5_754–4delTT in NSMCE4A (NM_001167865, coding for NSMCE4a protein). The mutations were conﬁrmed to be homozygous in subjects II.1 and II.2 and heterozygous in both parents by Sanger sequencing (Fig. 2B and Supplementary Fig. 2A).

The NSMCE4A c.754–5_754–4delTT is a novel variant near the splicing acceptor site of exon 6. The deleted nucleotides are not conserved in mammals and, in contrast to NFASC, NSMCE4A is not pre-ferentially expressed in nerve tissue, but rather in the bladder, colon, uterus, and prostate. Moreover, Mutation Taster and CADD did not predict this variant to be deleterious. NSMCE4A is tolerant to loss of function mutations (probability of being loss-of-function intolerant [pLI] 0.09, ExAC Browser) in contrast to the extremely intolerant pLI value of 1.0 for NFASC. However, analysis of the patients’ cDNA showed a higher expression of an alternative spliced transcript due to skipping exon 6 (XR_001747116.1) in addition to the normal transcript (NM_001167865) (Supplementary Figs. 2B–C), and a possible con-tribution to the disease cannot be ruled out.

The p.V1122E NFASC mutation is a novel variant absent from public databases. The valine at position 1122 is extremely intolerant pLI value of 1.0 for
transmembrane domain leading to impaired Neurofascin stability and function. Pathogenicity prediction tools SIFT, Provean, Polyphen2, Mutation Taster, Condel, and CADD were used to assess the impact of the identified variant. The NFASC p.V1122E mutation was predicted by all prediction tools to be deleterious (Fig. 2D). The cDNA analysis did not show a reduced amount of NFASC transcript in patients compared to controls.

Therefore, NFASC was prioritized as the candidate etiological gene in this family. To assess this hypothesis, functional studies were per-formed on iPSC-derived neurons.

3.3. Cellular and protein studies

Fibroblasts from the two affected siblings and three healthy controls were cultured from skin biopsies. Because Neurofascin is not expressed in fibroblasts, they were reprogrammed to iPSCs and then differentiated into mature neurons. Immunocytocfluorescence (ICF), performed at 50 days in vitro (DIV) showed a discrete Neurofascin distribution within controls neuron somata and several smaller spots of staining in neu-ronal somata and extensions (Fig. 3A–B). Neurofascin immuno-fluorescence was significantly reduced in patients (Student’s t-test, p = 0.005; Fig. 3C). Antibodies against the intracellular domain of Neurofascin exhibit cytoplasmic staining, representing the endosome-localized fraction of the protein [15]. A remarkable loss of Neurofascin was detected in neuronal cell bodies of patients, with less intense and more scattered staining (Fig. 3).

Immunoblotting neuronal lysates resulted in a single band at ~150 kDa, which is the predicted size of the longest protein isoform in humans. However, in adult human nerve tissue, protein glycosylation of Neurofascin results in observed molar-weights of 186 kDa and 155 kDa (Fig. 4A), corresponding to the neuronal and glial isoforms respectively. This molecular weight dis-crepancy may be explained by a different pattern of glycosylation in cultured cells [16] or by the expression of an alternative NFASC splicing isoform in iPSC-derived neurons.

Subcellular fractionation of cultured neurons showed prevalent membrane localization of Neurofascin, as expected [17], and a strong reduction of the protein in the membrane of patient-derived cells compared to controls (Student’s t-test, p = 0.005; Fig. 4D–E).

4. Discussion

We found a novel NFASC homozygous missense mutation in two siblings presenting with progressive infantile-onset ataxia with de-myelinating neuropathy. The variant causes the substitution of a hy-drophobic amino acid with a hydrophilic amino acid in the single transmembrane domain of the Neurofascin protein, suggesting a highly deleterious effect of the mutation. The functional studies described here are strongly consistent with NFASC being the most potential candidate gene, showing a significant reduction of the Neurofascin protein in iPSC-derived neurons from patients. However, a contribution of the splice variant of NSMCE4A remains plausible and requires further in-vestigation.

Considering that the amount of NFASC mRNA is not decreased in patients’ neurons, the reduction in Neurofascin is probably due to protein instability in membranes and accelerated turnover. Neurofascin is known to localize in the neuronal body, specifically at the level of the endo-lysosomal compartment. This would explain the punctate staining.
in ICF analysis, which is strongly reduced and scattered in neurons from patients, in line with the significant reduction in Neurofascin on Western blot analysis.

Neurofascin plays an essential role in central and peripheral nervous system development and function; therefore, it is biologically plausible that dysfunction of this protein can cause a composite neurological disorder. Previously described NFASC knockout mouse models have been reported to have a neurological phenotype with important nodal and paranodal involvement. NF155-null mouse mutants exhibit severe ataxia, motor paresis, and reduced nerve conduction velocities, with a mean survival of approximately 3 weeks. In these mice, paranodal ax-oglial junctions fail to form, and myelinated axons undergo degenera-tion [18,19]. NFASC mutants lacking both the glial NF155 and neuronal NF186 died at post-natal day 6 and exhibited an extensive disruption of the nodal-paranodal region in the central and peripheral nervous sys-tems, a strong reduction of nerve conduction velocities, and delayed/ reduced myelination of the central nervous system [7,9].

Two NFASC homozygous mutations (NM_001160331.1: c.1109G > C; p.R370P and c.2536C > T; p.R846X) were recently proposed as the cause of a severe neurodevelopmental disorder in two families [20,21]. The disease presented a highly pleiotropic clinical phenotype, variably characterized by global developmental delay, hy-pertonia or hypotonia, neonatal respiratory distress, intellectual dis-ability, areflexia, and facial dysmorphic features (hypertelorism, high and wide nasal bridge, micrognathia, glossoptosis, and cleft palate). Remarkably, brain MRI performed on one affected subject showed diffuse white matter T2 hyperintensity [21].

Smigiel et al. [20] reported immunofluorescence staining of skin biopsies from the probands, revealing an absence of the NF155 isoform at the paranode of myelinated axons and the disruption of the nodal axoglial complex. Localization of the mutation in an exon present only in the transcript encoding NF155 explains the specific absence of the glial isoform.

The variable clinical phenotype may be caused by several factors: the severity of the mutation, the selective involvement of distinct Neurofascin isoforms by pathogenic variants, and the presence of ge-netic modifiers. In any case, the intra-familial and inter-familial phe-notypic heterogeneity suggests a broad clinical spectrum associated with biallelic NFASC mutations. The description of additional cases is warranted in order to better define the NFASC-associated clinical phe-notypes.

Neurofascin is well known to clinical neurologists because a sig-nificant proportion of chronic inflammatory demyelinating poly-neuropathies (CIDPs) are caused by IgG4 antibodies against NF155 [22]. These cases are often associated with cerebellar ataxia and tremor [23]. Neuropathology on nerve biopsies shows minimal demyelination and a predominant injury to the nodes of Ranvier, which has prompted some authors to introduce the concept of nodopathy [24]. The nodes of Ranvier are ubiquitously present in myelinated structures of the central and peripheral nervous systems, including the cerebellum. The pheno-types associated with NFASC mutations clearly highlight the involve-ment of the central nervous system [20,21]. We propose expanding the

Fig. 3. ICF studies of iPSC-derived neurons. A-B) Skin biopsy-derived fibroblasts from the two affected siblings (II.1 and II.2) and three healthy controls (only CTR1 and CTR2 are shown) were reprogrammed into iPSCs and then differentiated into neurons. Confocal microscopy analysis showed discrete Neurofascin distribution (green) within control neuron somata and several spots of staining in neuronal extensions, whereas a remarkable loss and more scattered cytoplasmic staining of Neurofascin was detected in patients (bottom). 63× magnification (A) and 63× 2×-zoom magnification (B). C) Immunofluorescence quantification confirmed the statistically significant reduction of Neurofascin fluorescence in patients. * = p < 0.01. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
concept of nodopathy to central nervous system involvement, as there can be combined central and peripheral demyelination in anti-Neurofascin autoantibodies syndromes [22].

The neurophysiological results in the two affected siblings revealed slowing of the central and peripheral conduction velocities with more severe involvement of the central nervous system than the peripheral nervous system, and of motor fibers than sensory fibers, without conduction blocks, which are described as a common finding in acquired nodopathies [24]. The specific clinical neurophysiological features of patients with hereditary Neurofascin-related nodopathy could depend on the damaging potential of the causative mutation [25] and could be different from what is typically observed in acquired nodopathy [24], similarly to the differences commonly encountered between hereditary and acquired demyelinating polyneuropathies [26]. The issue of the neurophysiological spectrum of patients with genetic nodopathy should be addressed in future patients to better describe the pathophysiology and genotype-phenotype correlation.

In conclusion, the identification of NFASC as a causative gene for ataxia with demyelinating neuropathy paves the way for genetic re-search in the developing field of Neurofascin-related nodopathies of the central and peripheral nervous system.

Conflicts of interest

The authors report no competing interests.

Funding

This work was supported by funds from Fresco Institute for Parkinson’s disease to ADF.

LS was supported by Fondazione Umberto Veronesi.

Acknowledgments

We thank all of the family members for their cooperation with this study.

Appendix A. Supplementary data

Supplementary data to this article can be found online

References


Fig. 4. Immunoblot studies of iPSC-derived neurons. A) Immunoblot with anti-Neurofascin antibody comparing iPSC-derived neurons with an adult human brain. In iPSC-derived neurons, there is a single band at ~150 kDa, different from the bands at 155 and 186 kDa in the adult human brain. B-C) Immunoblots of neuronal lysates demonstrate a single band at ~150 kDa and a significant reduction of Neurofascin protein (approximately to half of the controls) in both patients (II.1 and II.2) compared to controls (CTR1, CTR2, and CTR3). D-E) Subcellular fractionation of cultured neurons showed prevalent membrane localization of Neurofascin and a strong reduction of the protein in the membranes of patient-derived cells compared to controls (p = 0.005). α-Tubulin and COX-IV are cytosol and membrane-fraction markers respectively. M = membrane, C = cytosol, * = p < 0.05, ** = p < 0.01.


